Home Tags HER2-Mutant NSCLC

Tag: HER2-Mutant NSCLC

DESTINY-Lung04 Delivers a First-Line PFS Advantage for Trastuzumab Deruxtecan in HER2-Mutant...

Results from a global Phase 3 trial demonstrated that trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) can delay disease progression longer than standard...